{"brief_title": "A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)", "brief_summary": "A study to assess the safety and efficacy of SU11248 in patients with gastrointestinal stromal tumor (GIST) whose disease has failed imatinib therapy or who were intolerant to imatinib treatment.", "condition": "Gastrointestinal Stromal Tumor", "intervention_type": "Drug", "intervention_name": "SU011248", "description": "50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.", "arm_group_label": "A", "criteria": "Key Inclusion Criteria: - Histologically-proven diagnosis of malignant GIST not amenable to surgery, radiation or combined modality treatment with curative intent - Failed Gleevec treatment or intolerant to Gleevec therapy Key Exclusion Criteria: - Treatment with any chemotherapy, chemoembolization therapy, immunotherapy, or investigational agent since the last dose of Gleevec", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00075218.xml"}